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Background: HIV/AIDS remains a major cause of morbidity and mortality in 
South Africa, with an adult prevalence rate of 17.9% in 2012. The massive 
antiretroviral (ARV) rollout has seen many more patients commenced on 
antiretroviral therapy (ART), and has transformed it into a manageable chronic 
disease. However, successful treatment is dependent on high rates of adherence 
to antiretroviral drugs. Recently there has been an increased utilisation of 
Designated Service Providers (DSP) by Healthcare Funders to manage 
escalating healthcare costs. This study aims to assess DSP pharmacy 
medication delivery to patients on antiretroviral therapy. 
 
Method: A retrospective cross-sectional descriptive study was conducted at a 
general family practice in the private sector, surveying all patients who received 
ART via DSP pharmacy services. Data was collected via an anonymous, self-
administered structured questionnaire and a review of clinical records. A total of 
40 patients were registered and initiated on ART at the sampled practice. 
Although 40 patients were available in the cohort only 34 participated.  
 
Results: A total of 34 patients (97.4%) participated in the study. Females 
(67.6%) between 30 and 50 years old employed in the public sector (53%) 
constituted the highest proportion of respondents. Most of the respondents were 
members of GEMS medical scheme (58.8%) followed by Discovery (14.7%) and 
Polmed (11.8%). The majority of the respondents (67.6%) have ART delivered to 
a doctor’s address; 20.6% receive medications from a pharmacy; and 11.3% 
collect their medications at a post office. Of the respondents, 88% received 
reminders providing medicine delivery details, with 82.4% receiving short 
message service (sms) reminders via cellular telephone. However, 23.5% of the 
respondents reported receiving medication late or never, and 29.4% received 
incorrect medications. The DSP pharmacy service was rated as poor or 
satisfactory by 29.4% of respondents, with 70.6% preferring to access ART from 
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their own doctor; 8.6% from a pharmacy of own choice; 5.9% from a courier 
pharmacy; and 14.7% from a DSP pharmacy. Significantly, 79.4% of 
respondents rated their adherence less than “excellent”; 17.6% missed doses; 
23.5% took ART > 2 hours late; and 33.4% missed doses in the last week. Of 
concern 32.4% of patients recorded viral loads > 50cp/ml and 5.9% recorded 
viral loads > 1000 cp/ml. Over a third of patients (38.3%) recorded CD4 levels < 
400. 
 
Conclusion: DSP Pharmacy Services provide an innovative and cost effective 
method of antiretroviral medicine delivery, however there is scope for service 
improvement.   Although most patients receive regular ARV medicine supplies, a 
significant number of patients receive incorrect medicines or no medicine at all, 
which may result in treatment interruptions and treatment failure. Successful ART 
requires near-perfect ARV adherence levels, however the majority of patients fail 
to maintain the required adherence levels. Most users of DSP pharmacy services 
rate the medicine delivery service poorly and the majority of patients prefer to 
access ART from their own doctor. ARV medicine access factors need to be 
carefully considered by medical schemes when ART treatment programs are 
designed, otherwise drug interruptions may result in poor adherence and in 
treatment failure. 
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ARV:  Antiretroviral        
DSP:  Designated Service Provider     
SEP:  Single Exit Price       
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NSDA: Negotiated Service Delivery Agreement    
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DMP:  Disease Management Program     
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CHAPTER I: INTRODUCTION  
 
1.1. Background  
South Africa has an estimated population of 52.98 million, with approximately 
5.26 million people living with HIV (PLHIV) and an overall HIV prevalence rate of 
approximately 10% (1). Geographically KwaZulu- Natal has the highest HIV 
prevalence (16.9%) and the eThekwini metropolitan where Durban is situated 
has a HIV prevalence rate of 14.5%.(2) An estimated15.9% of the population 
between the ages 15 and 49 years old were infected by HIV (1). Approximately 
17% of South African women of reproductive age are HIV positive. The 
prevalence of HIV amongst antenatal care patients has reached a plateau below 
30.2% in 2010 (3). Although the prevalence of HIV has levelled off, the absolute 
numbers of PLHIV is increasing by 100 000 per year (3).  
 The total number of patients receiving antiretroviral therapy increased from 47 
500 (95% CI 42 900 - 51 800) to 1.79 million (95% CI 1.65 - 1.93 million) 
between the middle of 2004 and the end of June, 2011. Of the patients receiving 
ART, 85% were receiving ART through the public health sector, 11% were 
receiving ART through disease management programmes in the private sector, 
and the remaining 4% were receiving ART through community treatment 
programmes run by non-governmental organisations (NGO’s) (4).The adult ART 
coverage rate based on CD4 counts < 200ul increased from 5.1% (95% CI 4.2 - 
6.1%) in the middle of 2004, to 79% (95% CI 80 - 85%) by the middle of 2011. 
The adult ART coverage using CD4 counts < 350ul was 52% (95% CI 46 - 57%) 
by the middle of 2011 (4). The incidence of new HIV infections has decreased by 
41%, from 2.43% in 2011, to 1.42% in 2011, with the mortality rate of HIV/AIDS 
decreasing by 27% in 2011. During 2011, there were 1 113 284 persons (15 
years and older) and 377 047 children (between 0 and 14 years old) in need of 
antiretroviral therapy (3).   
The private health sector plays a major role in HIV and AIDS care in South 
Africa, with over 100 000 (mid 2006) patients enrolled in Disease Management 
Programs (DMPs) (5).The private sector affords patients easier access to 
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HIV/AIDS care, but concentrates more on HAART with poor collaboration 
between it and the public health services (5).The private sector role players 
include Medical Scheme Beneficiaries (15% of population), Workplace Treatment 
Programs, Community Treatment Programs and Individuals paying for their own 
treatment. Data from the private sector indicates an 86% survival rate in patients 
following 12 months of ART. Discovery medical scheme also reported an 8% 
increase in survival rate of patients on ART, from 76% in 2010 to 84% in 2012 
(3). 
The Medical Schemes Act 131 of 1998 requires Medical Schemes to provide 
Prescribed Minimum Benefits (PMBs) in relation to HIV, and prohibits medical 
schemes from refusing high risk patients and loading premiums. PMBs in relation 
to HIV include: 
 HIV Counseling and testing 
 Screening and Prevention of TB 
 Diagnosis and Treatment of STIs 
 Treatment of Opportunist Infections 
 Prevention of Mother to Child Transmission 
 Post Exposure Prophylaxis 
 Medical Management and medications as prescribed within National 
Public sector Guidelines 
Healthcare Funders (Medical Schemes) have established Disease Management 
Programs (DMPs) and Designated Service Providers (DSPs) to reduce costs, to 
improve patient outcomes to and meet legislative requirements.(6)   
A study by Johnson to assess the number of patients accessing HAART in the 
private sector via DMPs, reported that there were 67 600 patients receiving 
HAART in the private sector in mid-2006. There was over 17 DMPs with 55 900 
patients on HAART. The majority of DMP patients on HAART (46 800) were 
treated by Aids for AIDS (36%), Lifesense (15%), Discovery (11%), Arum Health 
(11%), Qualsa (11%), respectively. Community Treatment Programs, Right to 
Care, SA Catholics Bishops Conference and Treatment Action Campaign had 11 
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600 patients on HAART in mid 2006. The Johnson study estimates a 32% annual 
growth in patients on HAART in the private sector (7). 
 
1.2. Problem statement 
DSP pharmacy services are increasingly being utilised by medical schemes to 
provide antiretroviral medications to patients. Successful HIV management is 
dependent on near perfect adherence to ART which is in turn dependant on a 
reliable supply of antiretroviral medications. Anecdotal evidence suggests the 
patients experience challenges with DSP pharmacy medicine deliveries. Any 
factor that may impact on ART adherence warrants concern, therefore an 
assessment of DSP pharmacy medicine delivery has been undertaken.  
   
1.3. Purpose of Study 
 This study aims to assess the process of DSP pharmacy medication delivery, 
patient satisfaction with and adherence to HIV treatment, whilst receiving 
medication through a DSP at a family practice. 
 
1.4. Specific Objectives 
The objectives of the study are: 
1. To review clinical and social demographic profile of patients receiving 
ARVs via DSPs at the general practice. 
2. To evaluate the process of medicine delivery to patients from this practice 
via DSPs  
3. To determine patient satisfaction with DSP services 
4. To assess patient adherence to ART through the DSP process  
5. To make recommendations based on findings of the study 
 
1.5. Structure of Dissertation 
This study is presented in 6 chapters: 
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Chapter I (Introduction) provides an introduction with a discussion of the 
background of the study, purpose of the study, and specific objectives of the 
study. 
Chapter II (Literature Review) presents a literature review of the current evidence 
regarding HIV treatment and designated service providers. 
Chapter III (Research Methodology) explains the study research design, study 
population, sample determination, inclusion and exclusion criteria, data collection 
and data handling and analysis. 
Chapter IV (Results and Analysis) describes the interpretation and explanation of 
the study findings in line with the objectives of the study. 
Chapter V (Discussion) presents a discussion in line with the objectives of the 
study. 
Chapter VI (Recommendations and Conclusion) presents a summary of the 




















CHAPTER II: LITERATURE REVIEW 
 
2.1. Introduction 
This chapter reviews existing evidence pertaining to HIV treatment and 
designated service providers (DSPs’). A literature review was conducted through 
Pubmed and Google Scholar using the following keywords: HIV, adherence, 
Antiretroviral, HAART, prevalence, designated service providers, private sector,  
healthcare funders, South Africa, KwaZulu-Natal and, Ilembe. This was done to 
provide information on Designated Service Providers and the law pertaining to 
them, as well as factors that affect adherence to HAART. 
 
2.2. Designated Service Provider Legislation  
Regulation 7 of the Medical Schemes Act defines a DSP as a provider or group 
of providers selected to provide the diagnosis, treatment and care in respect to 
one or more Prescribed Minimum Benefit (PMB) condition.” DSP” within the 
regulations is only used for the management of PMBs and all other managed 
health care conditions utilise “participating providers” (8).  
The appointment of DSPs is not well regulated within South African law, with only 
a few legal provisions applicable.(8) Legal provisions that impact on DSP 
arrangements are found within the Medical Schemes Act 131 of 1998, Health 
Professionals Council of South Africa (HPCSA) rules in terms of the Health 
Provisions Act (2006 HPCSA Policy on Undesirable Business Practice), and the 
Competition law and the Consumer Protection Act 68 of 2008. 
Medicine pricing in South Africa is tightly regulated with medicines sold at a 
regulated Single Exit Prices (SEP). Discounts and incentives are not permitted 
within the Medicines and Related Substance Amendment Act 72 of 2008 (section 
18A). 
 
2.3. Designated Service Providers in Healthcare Provision 
DSP arrangements have resulted in both positive and negative effects on 
healthcare provision. Lower cost of service, security of supply, and service 
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specific investment have been mentioned as positives, however DSP contracts 
can have the effect of being anticompetitive and of promoting collusion and 
reducing patient freedom of choice (6).  
A recent survey by Old Mutual Actuarial Consultants found that 60% of medical 
aid members had a negative attitude towards DSPs (31% wanted freedom of 
choice, 13% wanted to see their own doctor, and 9% found it inconvenient). The 
majority of DSP agreements involved general practitioners or pharmacies. 
Geographic coverage was listed as the biggest problem in appointing DSPs. 
Eighty percent (80%) of open schemes had DSP contracts with pharmacies. DSP 
agreements have shown substantial savings with general practitioners (60%) and 
pharmacies (80%), however medicine savings have been minimal (10%) (9). The 
minimal savings may be due to the effect of the single exit pricing of medicine.  
 
2.4. Role of Private Sector Doctors 
The demand for HIV care has placed a huge demand on healthcare services. 
Private health sectors doctors, especially primary care doctors, play an important 
role in providing HIV services. In 2006, the WHO reported that approximately 
21% of patients receiving ART in six African countries (SA, Nigeria, Uganda, 
Namibia, Botswana, and Kenya) were receiving treatment in the private sector. 
Private sector facilities offer more convenience to patients with shorter waiting 
times and more flexible schedules, are usually closer to home or work and some 
patients perceive private sector facilities as offering more confidentiality and 
sensitivity towards HIV patients. Despite the potential benefits, there have been 
concerns about quality, training, prescribing standards, testing and monitoring of 
patients, counselling, and the management of opportunistic infections. Changes 
in regulation, clinical training and ongoing education have improved clinical HIV 
management. A recent study in 2010 conducted in the KwaZulu Natal EThekwini 
region to assess whether private sector doctors manage patients in accordance 
with international and national guidelines, concluded that the majority of doctors 
were compliant with current HIV management guidelines, therefore maintaining 
an acceptable quality of care (10). 
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2.5. HIV Adherence 
Antiretroviral treatment has transformed HIV into a chronic manageable illness 
with median life expectancy now increased substantially (a 25 yr old on treatment 
now has an additional 39 years life expectancy in developed countries) (11). 
However, successful treatment outcomes are dependent on sustained high rates 
of adherence i.e. appropriate dose, at the appropriate time, in the appropriate 
manner (viz. with or without food) (12).  An antiretroviral adherence rate > 95% is 
required to ensure treatment success. Studies suggest that antiretroviral 
adherence rates of between 70% and 89 % are associated with viral rebound 
and the emergence of drug resistance. Non-adherence to ARVs results in: the 
emergence of debilitating constitutional symptoms; more opportunistic infections; 
more damage to vital organs by inflammatory processes; an increased chance of 
transmitting HIV to others; and substantial financial costs to both individuals; 
healthcare funders; and general society. Second and third line antiretroviral 
regimes are more complex; consist of more medications; cost more; are 
associated with more side effects and toxicities; and require more management 
and expensive laboratory tests (genotyping, phenotyping) (11).  
Maintaining adequate adherence rates remains the greatest challenge for 
patients on ARVs. Non-adherence rates to treatment range from 33% to 88% in 
studies, depending on how adherence is defined and assessed. A systematic 
literature review to examine the factors that affect adherence to treatment 
showed that factors common to patients in developed and developing counties 
were: 
  fear of disclosure 
  forgetfulness 
  lack of understanding of treatment benefits 
  complicated regimes  





 In developing countries common factors were: 
  Patient related factors (eg. patient beliefs, side effects, addiction, 
concurrent illness) 
  financial constraints  
  disruption to access to medication (13). 
 
2.6. Summary 
Adherence to antiretroviral medication is one of the most important factors 
required for HIV viral suppression and treatment success. A secure, reliable, 
regular supply of antiretrovirals is an important factor for successful outcomes. 
The recent introduction of legislative changes has empowered healthcare 
funders to increasingly utilise DSP pharmacy services in order to provide 
antiretroviral medications to medical aid members. This study aims to assess the 




















CHAPTER III: METHODOLOGY 
 
3.1. Introduction 
The following chapter gives a brief outline of the research design adopted for the 
study, the study population, the sample size determination, the location in which 
the research was carried out and the inclusion and exclusion criteria. 
 
3.2. Type of Research 
Epidemiological Study 
 
3.3. Research Methodology 
 
3.3.1. Study Setting 
The study was conducted at the researcher’s general family practice situated in 
Tongaat, a small coastal town on the KwaZulu-Natal North coast and part of the 
eThekwini municipality. Tongaat serves as business centre for the surrounding 
sugar farming industry and other associated small industries. Tongaat is serviced 
by a public sector primary healthcare facility and a private hospital (Mediclinic 
Victoria Hospital). The medical practice operates as a general family practice 
with approximately 5-10 patients on ART seen per day. The racial profile is 
approximately 70% black and 30% Indian. Almost 80% patients are medical 
scheme members and 20% are self funded. 
 
3.3.2. Study Design 
This study was a retrospective cross-sectional descriptive study was adopted for 
this study.  
 
3.4. Target Population 





3.5. Study Population 
Approximately 150 patients, comprising both self funded and medical scheme 
funded patients are seen per month at the research site with 40 patients 
receiving ARV medication via DSP pharmacy services. 
 
3.5.1. Inclusion Criteria 
All adult patients at the study site initiated on HAART and contracted to DSPs for 
delivery of ARVs. 
 
3.5.2. Exclusion Criteria 
 Children 
 All patients at the study site that receive HAART from the medical 
practice and not from the DSP pharmacy services. 
3.6. Study Sampling 
A purposive convenient sampling strategy was used to obtain the sample for the 
study. All patients who were contracted to DSPs for their ARVs were identified 
from medical records and contacted by the researcher to participate in the study. 
No patients were excluded, unless they declined participation. All prospective 
subjects were provided with a study information sheet and a consent form. 
 
3.6.1. Size of Sample 
A cohort of 36 patients accessing ARVs via a DSP pharmacy at the practice was 
identified. All patients were included in the study. Two patients declined to 
participate in the study. 
 
 
3.7. Data Collection 






3.7.1. Data Collection Tools 
1. Anonymous self-administered questionnaire. The questionnaire 
consists of 15 questions in 4 broad categories: 
a. Clinical and social demographic profile 
b. Process of Medication delivery 
c. Patient satisfaction 
d. Adherence to ART 
The questionnaire was available in the study participant’s choice of 
language (English or isiZulu). 
2. Review of Clinical Patient records: - viral load levels; CD4 
3. Pill counts  
3.7.2. Application of Data Collection Tools 
1. Study participants presented themselves to the medical practice 
where they were given a study information sheet (Appendix-1) and 
consent forms (Appendix-2). Once informed consent was obtained, 
the patient was given a study questionnaire (Appendix-3) to 
complete independently in a private setting. The researcher and 
trained research assistant were on hand to explain or clear up any 
unclear or ambiguous questions. Once completed, the 
questionnaires were checked for completeness and retained by the 
researcher.   
2. A records review tool was developed to review patient’s clinical 
records. Patients were encouraged to attend the medical practice at 
least monthly, where they were clinically examined for treatment 
failure and blood samples were drawn when required as part of 
their usual care and expenses. Viral load and CD4 counts were 
done every 3 months.    
3. Pill counts of patient ARVs were conducted monthly when patients 
presented themselves for clinical review, or decided to pick up 
delivered medication. Patients were requested to bring the previous 
12 
 
month’s medication boxes and bottles when visiting the medical 
practice. 
3.7.3. Data Handling 
Questionnaires that were filled in were handed over to the researcher, who 
stored them securely in a locked cabinet, which was only accessed by the 
researcher. Questionnaires were checked for completeness, factual inaccuracies 
and inconsistencies, and numbered to facilitate tracking later when data was 
entered onto a database. The coding scheme for variables was incorporated into 
the questionnaire design, allowing data to be entered directly into a database. 
The database was created using the IBM SPSS statistical software package. 
Data was entered directly into the database without using a separate coding 
sheet so as to minimise the introduction of data handling errors. All data entries 
into the database were double checked against the questionnaires for 
correctness. The completed database was then examined for inconsistencies 
and outliers. Frequency figures for each question were produced, which quickly 
showed outliers and inconsistencies. The computer database was password 
protected and backup copies were securely stored. 
 
 3.7.4. Data Analysis 
Descriptive statistical analysis was conducted. Means, proportions, percentages 
and confidence intervals were calculated and the results summarised in tables 
and graphs. The data within the database was grouped into categories to 
analyse according to the objectives of the study. The following categories were 
used: 
1. Demographic profile: the gender distribution of patients was summarised using 
a pie diagram and frequency tables were used to summarise the medical aid 
membership, level of education and occupation of patients utilising DSP 
pharmacy services. The age distribution of patients accessing ARV’s via 
pharmacy DSP services was summarised using a bar graph. 
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2. Clinical profile: a frequency table was used to summarise how long patients 
have been on ART before participating in the study and a pie diagram was used 
to summarise where patients first commenced their ART. 
3. Medicine delivery process: the number and percentage of patients receiving 
ARV’s at various possible delivery sites was summarised using a frequency 
table. Data regarding whether ARV’s were delivered on time, whether delivery 
reminders were received and whether correct medications were delivered, was 
summarised on a frequency table. These questions all required a yes or no 
response. Data pertaining to the type of reminders received before medicine 
delivery was summarised on pie diagram showing number and percentage. The 
data regarding when, if ever, incorrect medicines were delivered was 
summarised using a bar graph. 
4. Patient satisfaction: a frequency table was used to summarise the data 
regarding how satisfied patients were with the DSP pharmacy’s medicine 
services. Data pertaining to where patients would prefer to access their ARV 
medication was summarised using a pie graph. 
5. Adherence to ARV’s: frequency tables were used to summarise data regarding 
the number of ARV doses missed in the last 7 days, and the number of ARV 
doses taken > 2hrs late in the last 7 days. A bar graph was used to summarise 
data pertaining to when last a patient had missed an ARV dose. Bar graphs were 
used to summarise data regarding patient ARV adherence. 
 
3.8. Ensuring Validity and Reliability 
Each stage of the study (data collection, data maintenance, data processing and 
reporting) was carefully planned to avoid the introduction of error, thereby 
ensuring validity and reliability. 
 A self-administered questionnaire was chosen, because it offers some degree of 
anonymity and is not influenced by the interviewer. The questions were designed 
to be short, simple, specific, as well as easy to read and understand, thus 
promoting the greatest number of accurate answers and completed 
questionnaires. The questionnaire was available in the participant’s choice of 
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language (English or isiZulu). General questions were asked first, followed by 
more specific questions to encourage a better response rate. To avoid a time 
memory bias, time frames were kept to < 6 months where possible and wide time 
scales were used. Wherever possible, closed type questions, questions with 
fixed answer options, Likert-type scales, and visual analogue scales were used. 
This makes the questionnaire easier and quicker to complete, encourages 
respondents to complete the questionnaire, and allows for easier, more accurate 
coding of data, therefore reducing the introduction of bias. The questionnaire was 
designed with the coding of the answers built in, so that responses could be 
entered directly into the software programme, without the need to first code and 
transcribe. This reduces the risk of introducing bias in the data processing stage 
and ensures reliability. 
 All adult patients receiving antiretroviral medications via a DSP pharmacy 
service at the research site were identified and invited to participate, thereby 
reducing the risk of introducing a selection bias. Prospective study participants 
were all telephonically invited to participate. The questionnaire administration 
process was planned and the research assistant was trained to administer the 
questionnaire according to strict rules. The researcher or research assistant was 
always on hand to clarify any unclear or ambiguous questions. Completed 
questionnaires were immediately received by the researcher, who numbered 
them and stored them in a secure locker. 
In order to ensure study validity questionnaire responses were corroborated with 
practical observations e.g. delivery of medicines and clinical observations. There 
is no gold standard measure available for use in this study. However, wherever 
possible, established instruments were used to ensure validity. A recent study by 
Chaiyachati et al to assess the validity of a questionnaire with five questions, 
which assess adherence to antiretrovirals in the public sector, was conducted 
(14). These questions were included in the study. Various validation strategies 
were used to triangulate data.  The responses received on the questionnaire 
were verified against clinical data, delivery data records and patient records, 
thereby ensuring factual validity. Consistency checks were built into the 
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questionnaire by asking similar questions more than once. In order to ensure 
face validity, respondents were interviewed by the researcher after the 
questionnaire was filled out, in order to assess if answers corroborated 
questionnaire responses. The interview questions were posed differently, 
however they were based on those of the questionnaire. The questionnaire 
responses that seemed unusual were also verified during the interview.  
The study was conducted in a confined local area; therefore the study outcomes 
will only be applicable to areas with similar patient profiles, demographics and 
socio-economic characteristics.   
 
3.9. Ethical Consideration 
This study was approved by the University of KwaZulu-Natal Biomedical 
Research Ethics Committee (ref: BE071/13).The 4 principles of ethics 
(autonomy, justice, beneficence, non-maleficence) were addressed. It was 
conducted in the researcher’s own medical practice, by means of a self-
administered questionnaire. The participants were given full information 
regarding all risks and benefits, methods and purpose of the study, in the 
language of their choice, before participating. Study participants were not 
coerced in any manner and were free to accept or reject participating in the 
study. The study participants were chosen fairly consistent with the priorities of 
the study. The questionnaires were anonymous and were handled only by the 
researcher and research assistant. Participants were guaranteed confidentiality 
and questionnaires were stored securely .The study was carefully designed to 
avoid any risk or harm to study participants. This research project aims to 
enhance current knowledge regarding delivery of antiretroviral medications by 








CHAPTER IV: RESULTS AND DATA ANALYSIS 
 
4.1. Introduction 
This chapter describes the interpretation and explanation of the findings of the 
study, in line with the objectives of the study. The results are discussed under the 
following subtopics: demographic and clinical profile; medicine delivery process; 
patient satisfaction; and adherence and clinical outcomes. A total of 34 patients 
accepted and participated in the study, yielding a response rate of 94.74 percent. 
 
4.2. Demographic Profile 
 
4.2.1. Gender Profile 
The majority of the respondents namely 23 of the 34 respondents (67, 6%) who 





Figure 4-1: Gender profile of patients accessing ART via DSP pharmacy at 




4.2.2. Age Profile 
The majority of respondents accessing ARV’s via DSP pharmacies were aged 
between 31 and 50 years old, with 38.2% between 31-40 years old and 35.3% of 
all respondents between 41-50 years old. Patients between 21-30 years of age 
accounted for 17.6% of all respondents. Only 2.9% of the patients on ARV’s were 






Figure 4-2: Age distribution of patients accessing ART via DSP pharmacy 




Public Sector employees account for the majority of patients, with educators 
numbering 11 respondents (32.4%) of the sample, police personnel accounting 
for 4 (11.8%) and nurses numbering 3 of 34 respondents (8.8%). The balances 
of the respondents represent a wide spectrum of occupations, from pensioner, 
housewife, to local political councillors, reporters and truck drivers etc.             





Table 4-1: Frequency distribution of occupation of patients accessing ART 
via DSP pharmacy at a medical practice in Tongaat, KZN in 2013 
 
Occupation Number % 
   
Admin Clerk 2 5.9 
Artisan 1 2.9 
Assistant 2 5.9 
Councillor 2 5.9 
Educator 11 32.4 
House wife 1 2.9 
Manager 1 2.9 
Nurse 3 8.8 
Pensioner 1 2.9 
Police 4  11.8 
Receptionist 1 2.9 
Reporter 1 2.9 
Student 1 2.9 
Supervisor 1 2.9 
Truck driver 1 2.9 









4.2.4. Level of Education 
Most patients (88.2%) matriculated from school, with 52.9% of patients (18 of 34 
respondents) achieving post matriculation qualifications, with 2.9% (1respondent) 
that held a technical certificate. There were 12 respondents (35.3%) who 
matriculated from school with no further tertiary education, and 3 respondents 




Table 4-2: Frequency distribution of the level of education of patients who 
access ART via DSP pharmacy at a medical practice in Tongaat, KZN in 
2013  
 
Level of Education Number % 
   
Post matric qualification 18 52.9 
Matriculation 12 35.3 
Secondary education 3 8.9 
Technical certificate 1 2.9 






4.2.5. Medical Scheme 
A wide variety of medical schemes offer medical cover to the patients. 
Government Employees Medical Scheme (GEMS) represent 20 (58.8%) of the 
study sample, with Discovery Medical Scheme representing 5 (14.7%) and 
Polmed Medical Scheme representing 4 (11.8%) patients on ARV therapy. 
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Bonitas Medical Scheme and Medshield Medical Scheme both represent 2 
(5.9%) patients each. A single patient (2.9% of sample) is represented by SABC 





Table 4-3: Frequency distribution of medical scheme membership of 
patients receiving ART via DSP pharmacy at a medical practice in Tongaat, 
KZN in 2013 
 
Medical Scheme Number % 
   
Bonitas 2 5.9 
Discovery 5 14.7 
GEMS 20 58.8 
Medshield 2 5.9 
Polmed 4 11.8 
SABC 1 2.9 





4.3. Clinical Profile 
 
4.3.1. Duration on ART 
Patients enrolled in the study have been on ARVs for varying periods of time. 
The longest a patient from amongst those included in the study has been on 
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medication is 16 years, having commenced ARV therapy in 1997. Three patients 
(8.8% of sample) have been on medications for over 10 years. A total of 7 
patients (20.6%) were on treatment for 2-3 years, 5 patients (14.7%) were on 
treatment for 3-4 years, 7 patients (20.6%) were on treatment for 4-5 years and 9 
patients (26.5%) were on treatment for > 5years. Only 3 patients (8.8%) of the 




Table 4-4: Frequency distribution of time since commencing ART in 
Patients who obtain medication via DSP pharmacy at a medical practice in 
Tongaat, KZN in 2013 
 
Time since Commencing ARV’s  Number % 
0-1 year  3 8.8 
2-3 years  7 20.6 
3-4 years  5 14.7 
4-5 years  7 20.6 
5-10 years  9 26.5 
> 10 years  3 8.8 




4.3.2. ART Regimen 
The largest proportion of patients, 20 (58.8%), were first started on ARV regimen 
by the General Practitioner (GP). Only 2 (5.9%) were first commenced on ARVs 
at the Government Clinic, before transferring to private sector GP’s. The other 
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respondents first commenced ARV medication under Specialist medical care and 







Figure 4-3: Commencement site of ART in patients who receive ART via 







4.4. Medicine Delivery Process 
 
4.4.1. Point of Delivery 
Patients who subscribe to DSP Pharmacy Services have their medicines 
dispensed by a DSP Pharmacy (eg. Medipost, Pharmacy Direct etc.), which are 
then couriered to a chosen address or post office. A large proportion of 23 
(67.6%), chose to have ARV’s delivered to the doctor’s address for pick-up. A 
total of 7 (20.6%) of the respondents chose to pick up their ARV’s from a 
pharmacy and 4 (11.8%) preferred their medications delivered to a Post Office. 
None of the respondents chose to have ARV’s delivered to a home address.  






Table 4-5: Frequency distribution of delivery address for ART of patients 
who receive medication via DSP pharmacy at a medical practice in 
Tongaat, KZN in 2013 
 
Delivery address of ARV’s  Number % 
Doctor  23 67.6 
Pharmacy  7 20.6 
Post Office  4 11.8 
Home  0 0 







4.4.2. Reliability of Medicine Delivery 
The majority of patients, 76% (26 of 34 respondents) report receiving ARV 
medication deliveries on time, with 8 patients (23.5%) not receiving their ARVs 
on time. In those patients who receive medication deliveries, 30 patients (88.2%) 
report receiving a reminder before delivery, and 4 patients (11.8%) report 
receiving no delivery reminders at all. The 26 patients (70.6%) who received 
regular medicine deliveries report receiving correct medications, whereas 8 




Table 4-6: Frequency distribution of ARV medication delivery in patients 
receiving medication via DSP pharmacy at a medical practice in Tongaat, 
KZN in 2013 
  
Response Are ARVs 






    
Yes 26(76.5%) 30(88.2%) 26(76.5%) 
No 8(23.5%) 4(11.8%) 8(23.5%) 








SMS messages are the most popular method used to inform patients of an 
impending medicine delivery. A total of 28 patients (84.4%) of all respondents 
report receiving SMS messages. Telephone call reminders were received by 4 
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patients (11.8%) and 2 patients (5.9%) reported receiving no reminder.           








Figure 4-4: Types of reminders patients receive before receiving ARV 
medication delivery via DSP Pharmacy at a medical practice in Tongaat, 








4.4.4. Incorrect Supply of Medicines 
Twenty-four respondents (70.6%) reported always receiving correct medication 
deliveries; however 10 respondents (29.4%) reported receiving incorrect 





Figure 4-5: Incorrect ARV medication delivery to patients who access ART 





4.5. Patient Satisfaction 
The majority of patients (70.6%) rated their satisfaction with the service between 
good and excellent. Only 29.4% (10) of patients rated the service satisfactory or 
poor. (see Table 4-7). 
 
  
Table 4-7: Frequency distribution of patient satisfaction in patients who 
receive ART via DSP pharmacy at a medical practice in Tongaat, KZN in 
2013 
 
Patient Satisfaction  Number % 
Excellent  11 32.4 
Very Good  5 14.7 
Good  8 23.5 
Satisfactory  6 17.6 
Poor  4 11.8 




4.5.1. Patient Preferences 
The majority of patients (70.6%) reported that they prefer to access their ARV 
medications from their own doctor. A group of 5 patients (14.7%) preferred to 
access ARV medications from DSP pharmacies eg. Dischem, Clicks etc. A small 
group of 2 patients (5.9%) preferred receiving medications delivered by courier 
pharmacies eg. Medipost, and 3 respondents (8.8%) preferred to access their 





Figure 4-6: Where patients prefer to access their ART from in Patients who 





4.6. Adherence to Antiretroviral Therapy 
A group of 28 patients (82.4%) reported missing no antiretroviral medication 
doses in the last 7 days. There was however 3 patients (8.8%) who missed 1 
ARV dose in the preceding 7 days, 2 patients (5.9%) who missed 2 doses of 
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ARV’s in the preceding 7 days and 1 patient (2.9%) reported missing 4 ARV 




Table 4-8: Frequency distribution of the number of ARV doses missed in 
the last 7 days in patients who receive medication via DSP pharmacy at a 
medical practice in Tongaat, KZN in 2013 
 
No. of Doses Missed  Number % 
0  28 82.4% 
1  3 8.8% 
2  2 5.9% 
4  1 2.9% 







 A large proportion of patients sampled, 26 (76.5%) reported taking all ARV 
doses on time. There were 2 (5.9%) who took 1 ARV dose more than 2 hours 
late in the previous 7 days. A total of 5 (14.7%) respondents reported taking 2 
ARV doses more than 2 hours late. There was 1 patient who reported taking 4 




Table 4-9: Frequency distribution of the number of ARV doses taken > 2 
hours late in the last 7 days in patients who receive medication via DSP 
pharmacy at a medical practice in Tongaat, KZN in 2013 
 
No. of Doses >2 Hrs Late  Number % 
0  26 76.5% 
1  2 5.9% 
2  5 14.7% 
4  1 2.9% 





Six patients (17.7%) reported missing an ARV dose in the preceding week. It was 
reported that 2 patients (5.9%) had missed a dose “yesterday” and 4 patients 
(11.8%) had missed a dose “earlier this week”. There were 23 patients (67.6%) 
who reported never missing a dose. There were 3 patients (8.8%) who missed a 
dose “more than a month ago”, 1 patient (2.9%) missed a dose “less than a 
month ago” and 1 patient (8.8%) who missed an ARV dose “last week”.          









Figure 4-7: Missed ARV doses in patients who receive ART via DSP 
pharmacy at medical practice in Tongat,KZN in 2013 
 
 
There were only 7 patients (20.6%) who rated their adherence to have been 
“excellent”. A total of 27 patients (79.4%) reported suboptimal adherence, with 8 
patients (23.5%) who rated their adherence as “very good”, 16 patients (47.1%) 
who rated their adherence as “good”,1 respondent (2.9%) who reported “very 
poor”,1 respondent (2.9%) who reported “poor”, and 1 respondent (2.9%) who 







Figure 4-8: Adherence to ART as rated by patients receiving ART via DSP 





A total of 25 of 34 patients (73.5%) rate their adherence as having been between 
90-100 percent. Nine patients (26.5%) rated their adherence to have been less 
than 90%, with 7 patients (20.6%) rating their adherence to have been between 
80-89%, 1 patient (2.9%) between 70-79% and 1 patient between 40-49 percent. 





Figure 4-9: Adherence to ART rated on visual analogue scale by patients 






4.7. Clinical Outcomes 
 
4.7.1. Viral Load 
Viral loads measurements conducted revealed that there were 15 patients 
(44.1%) who recorded undetectable HIV viral loads, and 6 patients (17.6%) who 
recorded viral load levels between 20-49 copies/ml. A total of 9 patients (26.5%) 
of the study sample recorded viral load levels between 50-999 copies/ml. There 
were 2 patients (5.9%) who recorded HIV viral load levels greater than 1000 









Figure 4-10: Viral load measurements in patients who receive ART via DSP 











4.7.2. CD4 Count 
There were 4 patients (11.8%) with severe immune suppression, with CD4 cell 
counts less than 200 cell/uL, 9 patients (26.5%) recorded CD4 counts between 
201-400 cells/uL and 6 patients (17.6%) recorded CD4 cell counts between 401-
600/uL. A total of 13 patients (38.2%) recorded normal CD4 cell counts with 5 
patients (14.7%) recording CD4 counts between 601-800cell/uL, 6 patients 
(17.6%) with CD4 counts between 801-1000 cell/uL, and 2 patients (5.9%) 





Figure 4-11: CD4 cell counts in patients who receive ART via DSP 
pharmacy at a medical practice in Tongaat, KZN in 2013 
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CHAPTER V: DISCUSSION   
 
5.1. Introduction 
The unprecedented HIV treatment rollout in South Africa has yielded excellent 
results, and has dramatically changed the prognosis of HIV, with an 80% (ART 
eligible at < 200 /ul) adult coverage rate achieved by mid-2011. The life 
expectancy of patients has doubled since the introduction of HAART. The 
median survival time from seroconversion to death prior to HAART was 9.8 years 
and now has been extended to 13.3 years with HAART (4). HIV is therefore 
increasingly being regarded as a chronic, but manageable condition. Chronic 
disease management of HIV requires early detection of disease, sustained 
suppression of the viral load and restoration of immune function resulting in 
improved quality of life. 
 
5.2. Summary of results 
Females (67.7%) outnumber males (32.4%) in this study with 73.5% of 
respondents aged between 30 and 50 years old. The majority attained school 
matriculation (88.2%), and 52.9% achieved tertiary qualifications, with over half 
of all study participants employed in the public sector. In terms of insurance, 
GEMS represented 58.8% of all study participants, Discovery Medical Scheme 
14.7% and Polmed served 11.8 percent. 
At the time of study, 55.9% of study participants had been on ART for more than 
5 years, with 75.6% having started their treatment at private sector health 
practitioners. 
Although DSP pharmacy users could choose to receive ART via courier services 
at any delivery address or at a nearby DSP network pharmacy (Clicks, Dischem 
pharmacy), 67.6% of respondents chose to have ART delivered by courier to 
their doctors address. No respondents in this study chose to have ART delivered 
their home address, 20.6% preferred to pick up medication at a nearby DSP 
network pharmacy and 11.8% preferred to receive ART via the post office. Of the 
respondents, 88% received reminders providing medicine delivery details, with 
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82.4% receiving short message service (sms) reminders via cellular telephone. 
However 23.5% of the respondents reported receiving medication late or never 
and 29.4% received incorrect medications. DSP pharmacy service was rated as 
poor or satisfactory by 29.4% of respondents with 70.6% preferring to access 
ART from their own doctor, 8.6% from a pharmacy of own choice, 5.9% from a 
courier pharmacy and 14.7% from a DSP pharmacy. It is of significance to note 
that 79.4% of respondents rated their adherence less than “excellent”, 17.6% 
missed doses, 23.5% took ART > 2hrs late and 33.4% missed doses in the last 
week of their medication. Of particular concern was the fact that 32.4% of 
patients recorded viral loads > 50cp/ml, while 5.9% recorded viral loads >1000 
cp/ml. Over a third of patients (38.3%) recorded CD4 levels <400. 
 
5.3. Patient Demographics 
The gender distribution of this study, of 67.6% female and 32.4% male is in line 
with the data from Aid for AIDS which shows 74% of patients in the 25-45 yr age 
group, with 61% being female (5). This is consistent with a recent study that 
yielded a similar gender distribution with 61% female and 31% male (4). Several 
other studies have reported similar results with more women than men accessing 
HAART in both public and private healthcare sectors. The preponderance of 
females in HAART programs is partly due to the fact that there is a larger 
proportion of females than males infected with HIV in South Africa (in 2005 the 
ratio was1.2 female: male). Antenatal care programs have been very successful 
with screening, prevention and treatment of HIV. This is a common entry point for 
women into HAART programs. Women are also primary care givers and 
therefore interact more frequently with healthcare services. This familiarity with 
services provided by healthcare facilities may play a role in fostering female 
access to HIV care, specifically. Moreover, in South Africa most females are 
infected by their male spouses. It is thought that because men feel stigmatised 
by acquiring HIV outside of marriage that they don’t access HIV services as 
freely as women do (15). The gender imbalance in accessing HAART has severe 
consequences for men, who experience a greater rate of HIV related morbidity 
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and mortality than women. Although there is significant concern regarding the 
low uptake of HAART by men, disease management programs and NGO’s have 
not routinely collected and reported on age and sex of patients (4). 
 The prevalence of HIV in South Africa is highest in the 30 to 34 year age group, 
with the mean age of patients on HAART  in the 33 -38 years old age group (15). 
This suggests that patients are accessing treatment approximately 10 years after 
infection, when symptoms are most likely and when CD4 counts are low enough 
to qualify for HAART. The majority of participants in this study were in the 31 to 
40 year old age group (38.2%) and 41-50 year old age group, with 17.6% of 
study participants  in the under 30 years old age group.  
HIV management programs and the associated DSP pharmacy services that 
provide antiretrovirals to patients are complex structures, which patients often 
struggle to understand. Higher levels of education enable patients to understand 
the language and terminology used, to read literature provided by treatment 
programmes and to access services that are provided via complex, often new 
technology. The inability to understand and interact with these programmes often 
results in service failure, as well as patients not receiving their HIV treatment on 
time, which negatively affects adherence. Although the majority of the study 
participants (88.2%) attained school matriculation, with 52.9% achieving tertiary 
qualifications, anecdotal evidence suggests that patients struggle to solve DSP 
pharmacy service problems when they arise for one reason or another. 
 
5.4. Medicine delivery 
The closest DSP network pharmacy (Clicks, Dischem) is situated more than 20 
kilometres away from the study site. Patients have to access their medications 
via DSP courier pharmacies (Medipost, Pharmacy Direct) or travel to the DSP 
network pharmacies (Clicks, Dischem). Courier pharmacies offer patients a 
choice of whether to receive medicine at a delivery address or at a post office. 
Patients, who reside in rural or peri-urban areas, as is the case in this study, do 
not have reliable delivery addresses, and work place addresses are not favoured 
because of concerns over confidentiality. Courier DSP pharmacies are only 
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feasible if patients have fixed, reliable, secure personal addresses, otherwise 
they are inconvenient and may be unreliable and unsecure. DSP pharmacy 
services fared poorly in this study, with 76.5% of patients reporting antiretrovirals 
were not delivered on time, and more worryingly, 29.4% reported receiving 
incorrect medicines. A safe, efficient and reliable antiretroviral supply is an 
absolute necessity for successful HIV management. Medicine parcels are often 
collected by others on behalf of the patients, and may not be stored in 
appropriate conditions on their way to them. Therefore, many patients choose to 
use their doctors practice address for delivery of DSP courier medicines. This is 
clearly evident, with 70.6% of the study sample preferring to access their 
antiretrovirals from their own doctor, and not via a DSP pharmacy service. 
Furthermore couriers who deliver medicines for DSP pharmacy services are not 
trained in appropriate medicine handling, therefore medicines are often handled 
and transported in less than ideal conditions (medicine transported in vehicles 
with no temperature control, medicine parcels not handled with maximum care, 
medicines delivered but not picked up by patient left unsecured for long periods 
of time) which may impact on their effectiveness. The interaction between 
pharmacist and patient is important, especially so when it comes to antiretrovirals 
that have important drug interactions, side effects and special precautions. A 
large percentage of participants (82.4%) reported receiving SMS communication 
only, and only 5.9% report receiving telephone communication from DSP 
pharmacy services. Therefore, DSP pharmacy services have inadvertently 
resulted in a breakdown of the patient pharmacist relationship. Frequent, regular 
interaction with pharmacists ensures that patients take their medications safely 
and reliably. Furthermore, with antiretrovirals being delivered directly to patients, 
many patients feel less of a need to consult with their treating doctors regularly, 
except when they require repeat prescriptions. HIV is a complex illness to 
manage and requires frequent interaction with the patient. A breakdown in this 
healthcare provider patient relationship can result in poor adherence to treatment 




5.5. Patient Satisfaction 
The use of DSP’s by healthcare funders may help reduce the cost of healthcare 
services, but it also removes the patient’s freedom of choice, may affect 
efficiencies in service provision, and lead to diminished competition (6). In a 
recent OMAC healthcare survey (2010) conducted in south Africa, 60% of 
patients were negative towards DSP’s, with “lack of freedom of choice” cited as 
the main negative aspect (9). Patient satisfaction is an important ingredient for 
good adherence and eventual treatment success. Ten patients (29.4%) reported 
they were not satisfied with DSP pharmacy services, and rated the service as 
merely “satisfactory”, or “poor”. Only 14.7% of study respondents prefer to 
access their medications via DSP pharmacy services. 
 
5.6. HIV Adherence 
Although sustained adherence rates > 95% are required for treatment success, 
only 73.7% of study participants reported adherence rates > 90%, and 79.4% 
rated adherence as less than excellent. Patient self-report adherence measures 
are known to overestimate adherence by as much as 20%, but this is still 
considered the best measure of ARV adherence (16). A large proportion of this 
study sample exhibits suboptimal adherence to ARV’s and therefore is at risk of 
viral resistance and subsequent treatment failure. Barriers to ARV adherence in 
South Africa relate to: 
 Practical, environmental and service related problems 
 Lack of support by healthcare personnel 
 Poor HIV knowledge 
 Patients perceived lack of control over personal health 
 Discrimination (16) 
Currently, there is a paucity of information regarding DSP pharmacy services, but 
anecdotal evidence suggests they create numerous barriers to ART adherence. 
DSP pharmacy services are complex programmes with many role players, and 
complex administrative structures, which patients find difficult to understand and 
interact with. Therefore, patients experience difficulty solving service-related 
issues, which can result in drug delivery problems and treatment interruptions. 
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DSP pharmacy programs require patients to have knowledge and access to 
modern technology (fax, email, telephone) to effectively utilise services. Many 
areas surrounding the study area is rural, with poor access to modern technology 
with many patients having no computer literacy. Therefore patients have difficulty 
faxing or emailing medicine prescriptions to DSP pharmacies, as well as difficulty 
receiving drug delivery reminders and service messages.  As a consequence of 
receiving ART via couriers, many patients don’t consult with medical personal 
regularly, which can result in suboptimal HIV management. DSP pharmacy 
courier services rely on patients having a secure delivery addresses. A secure 
delivery address is critical to ensuring confidentiality and safe drug delivery. 
Many study respondents live and work in rural areas that have unreliable 
addresses, therefore these patients have difficulty utilising DSP pharmacy courier 
services. The study site has network DSP pharmacies located 20km away, 
therefore study participants don’t have a convenient alternative to DSP courier 
pharmacies. For this reason, patients have to incur excess expenses and are 
inconvenienced by having to travel large distances, at great effort to access DSP 
pharmacy services. Patients that are unable to utilise DSP pharmacy services 
and choose to access ART from non-DSP providers are often charged large co-
payments, which blocks easy access to ART. When patients are unable to afford 
co-payments, they are compelled to only use DSP services. This loss of freedom 
of choice in access to ART has a negative impact on ART adherence (11). 
 Successful HIV management programmes need to carefully identify barriers to 
adherence and design strategies to enhance compliance and to avoid treatment 
failure. Viral load levels > 50 copies/ml is an indication of virological failure, 
because drug mutations can occur at these levels (17).Overall 32.4% of the 
study sample met the criteria for virological failure, with 5.9% recording viral load 
levels > 1000 copies/ml. Patients with viral loads > 50 copies/ml require urgent 
intervention (adherence assessment, counselling and retesting) and those with 
viral load readings > 1000 copies/ml most likely have virological failure and 
require adherence counselling and a change of treatment regimen. The WHO 
defines immunological failure as having either: 
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 CD4 count < 100 cells/uL 6 months after commencing ART’s; 
 CD4 counts less or equal to the starting CD4 before commencing ART’s; 
 Or > 50% reduction from peak CD4 count while on ART. 
 
5.7. Study Limitations 
Although all prospective study participants were identified from medical practice 
patient files, and invited to participate in the study, the study relies on voluntary 
enrolment by participants. The study was conducted with a small sample size 
and in a confined local area where the study outcomes will only be applicable to 
areas with similar patient profiles, demographic and socio-economic 
characteristics. The anonymous self-administered questionnaire although 
carefully planned to avoid information bias does rely on patient recall. Pill counts 
and clinical records could not be used to validate patient response to ART 





















CHAPTER VI: RECOMMENDATIONS AND CONCLUSION 
 
6.1. Introduction 
This chapter presents a summary of the research study, the results and 
recommendations to policy makers and medical schemes, which can improve the 
DSP pharmacy medication delivery of ART to patients. 
 
6.2. Conclusion 
DSP pharmacy services supply ARV medications to a broad spectrum of medical 
aid members. Although most patients receive regular ARV medicine supplies, a 
number of patients receive incorrect medicines or no medicine at all, which may 
result in treatment interruptions and treatment failure. Successful ART requires 
near-perfect ARV adherence levels, however the majority of patients fail to 
maintain the required adherence levels. Most users of DSP pharmacy services 
rate the medicine delivery service poorly and the majority of patients prefer to 
access ART from their own doctor. ARV medicine access factors need to be 
carefully considered by medical schemes when ART treatment programs are 




DSP pharmacy services provide an innovative method for the delivery of ARV 
medication to members of medical schemes, however for the service to be more 
efficiently utilised, it requires intervention at the patient level and at the DSP 
provider level. Based on the finding of this study the following recommendations 
are given: 
 
At the patient level: 
1. Appropriate counselling by healthcare personnel about the importance 
of high levels of adherence needs to be emphasised. 
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2. Concentrated patient education and marketing needs to be directed at 
DSP pharmacy users so as to improve knowledge regarding DSP 
pharmacy services and the various service providers involved in rendering 
the medicine delivery service.  
  
At the Designated Service Provider level: 
1. At a policy level, DSP pharmacy service providers need to address 
better regulation regarding personnel that are employed for the provision 
of antiretroviral medicines to patients. Appropriately trained staff are 
needed to process medication claims and resolve ART queries; couriers 
ought to be educated on how medicine should be appropriately handled 
and transported, adequate numbers of properly trained pharmacists and 
pharmacy assistants are needed to efficiently and appropriately handle the 
dispensing of medications; and appropriately trained clinical staff is 
required to address ART related enquiries.  
2. The current process of ARV medicine provision needs to be assessed 
and enhanced so as to improve efficiency of medicine delivery. Creating a 
single point of contact for patients will streamline service provision and 
help patients to resolve service-related problems quickly and easily when 
they occur. 
3. Increased use of cellular phone, smart phone and tablet technology and 
related apps will help improve and simplify DSP pharmacy service access. 
4. The current DSP pharmacy networks need to be expanded, with more 
pharmacies and dispensing doctors so as to improve access to DSP 
pharmacy services to more patients in all areas.  
5. Regular audits of service provision and adherence to good pharmacy 
practice need to be conducted, and shortcomings quickly resolved. 
 
The researcher recommends a larger study be conducted that examines patient 
outcomes, with a broader population from across a more expansive area. 
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Furthermore clinical outcomes from patient charts and pill counts should be 
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STUDY INFORMATION SHEET 
TITLE OF STUDY: An Assessment of DSP Pharmacy Medication Delivery for 
HIV Treatment in a Family Practice in KwaZulu-Natal 
 
Dear Mr / Mrs / Ms ……………………………………………….Date: …../…../…….. 
1. PURPOSE OF THE STUDY 
I understand that I am being asked to participate in a research study. The aim of 
the study is to assess Designated Service Provider (DSP) pharmacy medication 
delivery for HIV treatment, patient satisfaction and adherence to HIV treatment. 
We wish to identify strengths and challenges and provide recommendations 
based on the findings of the study. 
2 .EXPLANATION OF PROCEEDURE TO BE FOLLOWED 
The study involves answering a questionnaire regarding the DSP (eg. Medipost, 
Direct medicines) that supplies your ARVs. 
3 .RISK AND DISCOMFORT INVOLVED 
I as a participant in this study will remain anonymous. I will have to fill in a 
questionnaire that will take 20 – 30 minutes and there is no other risk involved. 
4 .POSSIBLE BENEFITS OF THE STUDY 
Valuable information and lessons learned from this study will be shared with 
other Health care professionals. 
5. I understand that if I do not want to participate in this study, there are no 
penalties, and I will not be prejudiced in any way. 
6. I may at any time withdraw from this study. 
 
7. HAS THE STUDY RECEIVED ETHICAL APPROVAL 
This protocol is to be submitted to the Faculty of Health Sciences Research 
Ethics Committee, University of KwaZulu-Natal and written approval has to be 
obtained from that committee. The study has been structured in accordance with 
the Declaration of Helsinki which guides doctors in biomedical research involving 
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human subjects. A copy of the Helsinki Declaration can be obtained from the 
researcher should you wish. 
8. INFORMATION 
If I have any question you should contact researcher Dr V.V.Reddy: 0329441115 
(W) or 0822557272 (cell) 
9. CONFIDENTIALITY 
All information obtained during this study will be regarded as confidential. Study 
results will be published/presented in a manner that participants remain 
anonymous. 
10. IF YOU FEEL HARMED 
If you feel harmed in any way by participating in this study you can contact my 
























I have read or had read to me in a language that I understand the above 
information before signing this consent form. The content and meaning of this 
have been explained to me. I have been given the opportunity to ask questions 
and am satisfied that they have been answered satisfactorily. I understand that if 
I do not participate it will not alter my management in any way. I hereby volunteer 
to take part in this study. 
I have received a signed copy of this informed consent agreement. 
………………………………….   ………………………….. 
 Participant signature      Date 
………………………………………….   ………………………………… 
Person obtaining consent     Date 
………………………………………….   ………………………………… 
Witness       Date 
 
VERBAL PARTICIPANT INFORMED CONSENT (If participant cannot read or write) 
I, the undersigned, Dr V.V.Reddy or nurse have read and have explained fully to 
the participant the information leaflet, which has explained the nature and 
purpose of the study in which I have asked him/her to participate. I have 
explained the possible risks and benefits of the study. The participant indicates 
that she/he understands that she/he is free to withdraw from the study at any 
time without any prejudice. 
I hereby certify that the participant has agreed to participate in the study. 
 
Participants name: …………………………….. Signature:
 …………………………… 
 
















Highest Level of Education : 
…………………………………………………………………… 
 
1 .When did you start ARVs? 
…………………………………………………………………. 
 




3. Currently, where do u receive your ARV medication? (Choose one) 
Home                       pharmacy                     post office                             doctor 
 
 
4. Is your ARV medication delivered on time?          Yes                      No 
 
 






6. What type of reminder do you receive?  
    SMS                          email                           telephone call                      other  
  
7. Do you receive the correct ARV medication every month?            Yes              
No   
 
 
8. When did you receive incorrect medicine, short medicine or no medicine? 
a. 1 month ago  b. 2 months ago c. 3 months ago d. 4 months 
ago 




9. Rate your satisfaction with the DSP pharmacy delivery service on a scale 1 – 5 




10. I would prefer to receive my antiretroviral medication from: 




11. During the last 7 days, how many times in total did u miss taking one or more 
antiretroviral pills.:                    ………………………………times 
 
 
12. In the last 7 days, how many times in total did you take your ARV pills more 




13. How would you rate your adherence over the last month? (choose one) 
  a..Very poor 
 b. Poor 
 c. Fair 
 e. Good 
 f. Very good 
 g. Excellent 
 
 
14. When was the last time you missed your antiretroviral pill? ( multi-choice 
question) 
a .Today     b. Yesterday                        c . Earlier this week 
  
d. Last week     e. Less than a month ago  f. More than a 
month ago 
g. I have never missed 
 
 
15. Please put a cross on the line below at the point showing your best guess 
about how many antiretroviral pills you have taken in the last month.  0% means 
you have taken none of the pills, 50% means you have taken half your pills and 
100% means you have taken every single pill 
 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
 i………i……...i……..i……...i……...i……...i……...i……...i……...i………i 
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